KRAS and neoplasm: In the FLAURA study, mutations of KRAS, like G12D and A146T, were described in the cfDNA of 3% of cases [51]; in the study conducted by Schoenfeld on tumor tissue, KRAS mutation G12A was recorded in one case (4%) [54].